PBI 1393

Drug Profile

PBI 1393

Alternative Names: PBI-1393

Latest Information Update: 17 Jan 2011

Price : $50

At a glance

  • Originator Unknown
  • Developer ProMetic Life Sciences
  • Class Antineoplastics
  • Mechanism of Action Lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Jan 2011 PBI 1393 is available for licensing as of 17 Jan 2011. http://www.prometic.com/en/index.php
  • 13 Jul 2009 Preclinical development is ongoing in Canada
  • 07 Apr 2006 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top